Modality
Bispecific Ab
MOA
BETi
Target
Cl18.2
Pathway
Wnt
CeliacBreast Ca
Development Pipeline
Preclinical
May 2021
PreclinicalCurrent
NCT05426881
1,498 pts·Celiac
2021-05→TBD·Not yet recruiting
1,498 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
Preclinical
Not yet…
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05426881 | Preclinical | Celiac | Not yet recr... | 1498 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 |